PCG Advisory

The PCG Advisory is a dynamic digital media portal that aggregates, displays, and distributes relevant corporate developments through a variety of user-friendly outlets that include social media sites such as Twitter, Facebook, LinkedIn, and YouTube. Each Sector's News Room contains landing pages for innovative companies, which include research / profile reports, videos, news feeds, market data, company blogs, and links to digital media coverage across the Web.

Catheter Precision Announces Tender Win and First Purchase Order in Croatia
09/10/2025

Catheter Precision Announces Tender Win and First Purchase Order in Croatia

Catheter Precision Announces Tender Win and First Purchase Order in Croatia

09/09/2025

Quoin Pharmaceuticals has released its fifth episode in its nethertonnow.com video series. This installment features twin sisters Allie and Kaleigh Fasanella, both living with Netherton Syndrome, as they candidly share their lifelong struggles of managing this devastating disease. Quoin is advancing QRX003 in pivotal trials, with early data supporting its goal of bringing the first approved therapy for Netherton Syndrome. Watch the full episode here:

Coya Therapeutics, Inc. COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trialpcgadvisory.com/pcgnews/coya-the...
09/04/2025

Coya Therapeutics, Inc. COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
pcgadvisory.com/pcgnews/coya-therapeutics-coya-302-als-trial-accepted-by-neals-as-a-neals-affiliated-trial/

Catheter Precision $VTAK Announces Introduction of the LockeT Product Line into Italy
09/03/2025

Catheter Precision $VTAK Announces Introduction of the LockeT Product Line into Italy

Catheter Precision Announces Introduction of the LockeT Product Line into Italy

EdgeMode$EDGM is pleased to announce that it has entered into a Memorandum of Understanding (MoU) with Marviken ONE AB. ...
09/02/2025

EdgeMode$EDGM is pleased to announce that it has entered into a Memorandum of Understanding (MoU) with Marviken ONE AB. This collaboration underscores EdgeMode’s commitment to sustainable and resilient data center growth while supporting energy innovation in Sweden.

EdgeMode is pleased to announce that it has entered into a Memorandum of Understanding (MoU) with Marviken ONE AB. This collaboration underscores EdgeMode’s commitment to sustainable and resilient data center growth while supporting energy innovation in Sweden.

MetaVia to Present at Upcoming Investor and Industry Conferences
08/28/2025

MetaVia to Present at Upcoming Investor and Industry Conferences

MetaVia to Present at Upcoming Investor and Industry Conferences

NextNRG’s Patented RenCast™ Platform Tackles the Solar Energy Challenges Highlighted by President Trump
08/26/2025

NextNRG’s Patented RenCast™ Platform Tackles the Solar Energy Challenges Highlighted by President Trump

NextNRG’s Patented RenCast™ Platform Tackles the Solar Energy Challenges Highlighted by President Trump

Catheter Precision Receives Notification of New Patent Issuance for VIVO Product Line
08/26/2025

Catheter Precision Receives Notification of New Patent Issuance for VIVO Product Line

Catheter Precision Receives Notification of New Patent Issuance for VIVO Product Line

Insight Molecular Diagnostics $IMDX CFO Andrea James was featured on the Empowered Patient Podcast, discussing the compa...
08/25/2025

Insight Molecular Diagnostics $IMDX CFO Andrea James was featured on the Empowered Patient Podcast, discussing the company’s mission to democratize access to molecular diagnostics. The episode highlighted iMDx’s focus on transplant monitoring, its pathway toward FDA clearance, and global adoption of its RUO kit in research settings.
https://finance.yahoo.com/news/imdx-cfo-andrea-james-featured-131500754.html

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment ...
08/25/2025

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Address

New York, NY

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm
Saturday 9am - 5pm
Sunday 9am - 5pm

Telephone

+16468636893

Alerts

Be the first to know and let us send you an email when PCG Advisory posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to PCG Advisory:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram